AS-601811

Pharmaceutical compound From Wikipedia, the free encyclopedia

AS-601811 is a 5α-reductase inhibitor of type 1 of the enzyme which was under development for the treatment of acne, benign prostatic hyperplasia, hirsutism, male-pattern baldness, and prostate cancer but was never marketed.[1][2] It is taken orally.[1] The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1] It was being developed by Merck Serono.[1][2]

Other namesAS-601811; AS601811
Routes of
administrationOral[1]
Drug class5α-Reductase inhibitor
ATC code
  • None
Quick facts Clinical data, Other names ...
AS-601811
Clinical data
Other namesAS-601811; AS601811
Routes of
administration		Oral[1]
Drug class5α-Reductase inhibitor
ATC code
  • None
Identifiers
  • 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC15H17NO
Molar mass227.307 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C
  • InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3
  • Key:SNEPAAKJPPNOQM-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI